FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2093531337> ?p ?o ?g. }

• W2093531337 endingPage "1849" @default.
• W2093531337 startingPage "1825" @default.
• W2093531337 abstract "Background: Inhibitors of monoamine oxidase (MAO) with selectivity and specificity for MAO type B (MAO-B) prolong the duration of action of both endogenously and exogenously derived dopamine. Rasagiline [N-propargyl-l(R)-aminoindan] is a second-generation propargylamine pharmacophore that selectively and irreversibly inhibits brain MAO-B and is specifically designed for the treatment of Parkinson's disease (PD). Objective: The aim of this study was to review the pharmacology, tolerability, and clinical efficacy of rasagiline in the treatment of PD. Methods: MEDLINE (1966-April 2007), the Cochrane Database of Systematic Reviews, and International Pharmaceutical Abstracts (1970-April 2007) were searched for original research and review articles published in English. The search terms were monoamine oxidase, neuroprotection, Parkinson disease, propargylamine, rasagiline, and selegiline. The reference lists of articles were also consulted, as was information provided by the manufacturer of rasagiline. Results: Data from 63 clinical and laboratory studies were analyzed. Based on the results from those studies, we concluded that rasagiline PO QD, at the therapeutic dosage range of 0.5 to 1 rag/d, is effective and well tolerated and completely, selectively, and specifically inhibited MAO-B. Pharmacologically, rasagiline was found to be ≤10-fold more potent than selegiline and was not metabolized to amphetamine derivatives. Rasagiline was effective both as monotherapy in early PD and as adjunctive treatment in patients with advancing PD and motor fluctuations. As monotherapy, rasagiline provided modest yet clinically meaningful benefit. A randomized, double-blind, placebo-controlled study found that, after 26 weeks of treatment, the adjusted effect size for total Unified Parkinson's Disease Rating Scale score was –4.20 (95% CI, -5.66 to -2.73) for rasagiline 1 mg/d versus placebo (P < 0.001). Preliminary long-term data from an open-label study suggest a sustained therapeutic advantage when rasagiline is initiated early (before the need for dopaminergic agents) rather than later. In patients with more advanced disease who received treatment with dopaminergic agents, rasagiline and entacapone were associated with reductions of “off” time significantly greater than placebo (-1.18 and -1.2 vs 0.4 hour; both, P ≤ 0.001). Rasagiline was well tolerated in younger (aged <;70 years) and older (aged ≥70 years) patients with early or advanced PD. Pharmacologically, rasagiline has the potential to augment the vasopressor effects of diet-derived tyramine (ie, the “cheese reaction”). However, clinical challenge studies of tyramine have found this unlikely to occur even with ingestion of supraphysiologic amounts of tyramine. In experimental models, rasagiline has been found to have neuroprotective properties that may be independent of MAO-B inhibition. Conclusions: Based on this review, rasagiline has been found to be well tolerated and effective in the treatment of early PD and as adjunctive treatment in motor fluctuations. Whether rasagiline is associated with clinically significant neuroprotection (ie, disease modification) in PD is the subject of ongoing clinical trials." @default.
• W2093531337 created "2016-06-24" @default.
• W2093531337 creator A5025229446 @default.
• W2093531337 creator A5069937383 @default.
• W2093531337 creator A5074778432 @default.
• W2093531337 date "2007-09-01" @default.
• W2093531337 modified "2023-10-16" @default.
• W2093531337 title "Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's Disease" @default.
• W2093531337 cites W112085907 @default.
• W2093531337 cites W148549003 @default.
• W2093531337 cites W1491014419 @default.
• W2093531337 cites W1526193826 @default.
• W2093531337 cites W1533056363 @default.
• W2093531337 cites W1546157867 @default.
• W2093531337 cites W1562359367 @default.
• W2093531337 cites W1563482732 @default.
• W2093531337 cites W1586462676 @default.
• W2093531337 cites W17131581 @default.
• W2093531337 cites W187181932 @default.
• W2093531337 cites W1913964519 @default.
• W2093531337 cites W1963897463 @default.
• W2093531337 cites W1965983395 @default.
• W2093531337 cites W1966987284 @default.
• W2093531337 cites W1969280474 @default.
• W2093531337 cites W1969617718 @default.
• W2093531337 cites W1970341001 @default.
• W2093531337 cites W1970679628 @default.
• W2093531337 cites W1971684959 @default.
• W2093531337 cites W1974352826 @default.
• W2093531337 cites W1974490536 @default.
• W2093531337 cites W1976952682 @default.
• W2093531337 cites W1979297739 @default.
• W2093531337 cites W1979710386 @default.
• W2093531337 cites W1982916435 @default.
• W2093531337 cites W1985095405 @default.
• W2093531337 cites W1986216002 @default.
• W2093531337 cites W1990566123 @default.
• W2093531337 cites W1993831043 @default.
• W2093531337 cites W1993964261 @default.
• W2093531337 cites W1995410280 @default.
• W2093531337 cites W1995590349 @default.
• W2093531337 cites W1999880770 @default.
• W2093531337 cites W2000123233 @default.
• W2093531337 cites W2003125470 @default.
• W2093531337 cites W2004436319 @default.
• W2093531337 cites W2009524267 @default.
• W2093531337 cites W2010170013 @default.
• W2093531337 cites W2010244749 @default.
• W2093531337 cites W2015702292 @default.
• W2093531337 cites W201588874 @default.
• W2093531337 cites W2016388476 @default.
• W2093531337 cites W2016833889 @default.
• W2093531337 cites W2018792227 @default.
• W2093531337 cites W2019350197 @default.
• W2093531337 cites W2020474216 @default.
• W2093531337 cites W2020574016 @default.
• W2093531337 cites W2021357019 @default.
• W2093531337 cites W2021374461 @default.
• W2093531337 cites W2021494427 @default.
• W2093531337 cites W2023534158 @default.
• W2093531337 cites W2029049658 @default.
• W2093531337 cites W2031843850 @default.
• W2093531337 cites W2039566772 @default.
• W2093531337 cites W2039821298 @default.
• W2093531337 cites W2043951579 @default.
• W2093531337 cites W2044368552 @default.
• W2093531337 cites W2045729751 @default.
• W2093531337 cites W2046705186 @default.
• W2093531337 cites W2051176914 @default.
• W2093531337 cites W2052994532 @default.
• W2093531337 cites W2054411178 @default.
• W2093531337 cites W2064247543 @default.
• W2093531337 cites W2067346519 @default.
• W2093531337 cites W2072232675 @default.
• W2093531337 cites W2072394501 @default.
• W2093531337 cites W2073033007 @default.
• W2093531337 cites W2073991388 @default.
• W2093531337 cites W2076430038 @default.
• W2093531337 cites W2082953267 @default.
• W2093531337 cites W2085307991 @default.
• W2093531337 cites W2085975745 @default.
• W2093531337 cites W2089861999 @default.
• W2093531337 cites W2091818830 @default.
• W2093531337 cites W2093781635 @default.
• W2093531337 cites W2100252302 @default.
• W2093531337 cites W2104795285 @default.
• W2093531337 cites W2107095942 @default.
• W2093531337 cites W2111376434 @default.
• W2093531337 cites W2123778879 @default.
• W2093531337 cites W2132894148 @default.
• W2093531337 cites W2136406052 @default.
• W2093531337 cites W2136653208 @default.
• W2093531337 cites W2137669059 @default.
• W2093531337 cites W2145337544 @default.
• W2093531337 cites W2151320291 @default.
• W2093531337 cites W2152250921 @default.
• W2093531337 cites W2154535037 @default.
• W2093531337 cites W2163071819 @default.

• next